The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Immunotherapy in NSCLC: a perspective
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, provides an overview of recent trial data concerning the immunotherapy of non-oncogene addicted non-small cell lung cancer (NSCLC). Dr Scagliotti emphasizes the importance of exploring combinations of immunotherapy and other treatment modalities in a clinical setting.
